Growth stimulating factor in patients with comorbid pathology

Objective: to study the level of growth stimulating factor (sST-2) in comorbid patients with ST-segment elevation myocardial infarction (STeMI) who underwent PCI for 36 months. Materials and methods: the study included 191 people, 36.2 + 1.8 months of follow-up, and included the following stages: I stage (hospital) — from the moment of admission to the hospital for myocardial infarction; II stage (outpatient) — repeated visits 12 and 36 months after discharge from the hospital. The patients were divided into three groups: Group 1 — 69 patients with STEMI + hypertension; Group 2 — 67 patients with STEMI + hypertension + type 2 diabetes; Group 3 (comparison group) — 55 patients with hypertension and DM. Assessment of the plasma level of sST2 was carried out using kits of the company «Critical Diagnostics Presage RST2 Assay kit» (USA). The results were expressed in ng/ml. Results: the study showed that the level of the sST2 biomarker in patients with acute ST-segment elevation myocardial infarction(STEMI) and type 2 diabetes mellitus(DM2) had no significant differences between the groups. The sST2 values in these patients were significantly higher than in the comparison group. At the stage of hospitalization, the median sST2 in the first group (STEMI and HYPERTENSION) was 62.7 ng/ml, and in the second group (STEMI, hypertension and DM 2) — 56.3 ng / ml. After one year, the median decreased to 55.3 ng/ml and 52.4 ng/ml, respectively, and in the third year — to 46.4 ng/ml and 42.1 ng/ml. Correlations between sST2 values were not found in the acute period and after 12 and 36 months of pregnancy. A moderate association appeared in the 1st and 3rd year of follow-up. Conclusion: the study revealed that the level of the sST-2 marker in the groups of patients with STEMI\ + AH and STeMI + AH + DM at all stages of the study is comparable and significantly higher than in patients with hypertension + DM. During the study, a correlation was found between the levels of sST-2 outside the acute period of MI. However, there was no significant association between the marker levels at the hospital stage and its values at the end of the study. It was also found that the level of sST\-2 does not depend on the presence of diabetes and is associated with the final systolic, diastolic size and volume of.

Authors

Institutions

Publication Details

Journal
South Russian Journal of Therapeutic Practice
Published
2025-03-11
DOI
https://doi.org/10.21886/2712-8156-2025-6-1-66-72
Primary Topic
Apelin-related biomedical research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Growth stimulating factor in patients with comorbid pathology

В. А. Суроедов, O. V. Likhachev-Mishchenko, Л. А. Хаишева, N. V. Drobotya et al.
South Russian Journal of Therapeutic Practice
Apelin-related biomedical research
article

Growth stimulating factor in patients with comorbid pathology

В. А. Суроедов, O. V. Likhachev-Mishchenko, Л. А. Хаишева, N. V. Drobotya, K. A. Khaishev
article en

Abstract

Objective: to study the level of growth stimulating factor (sST-2) in comorbid patients with ST-segment elevation myocardial infarction (STeMI) who underwent PCI for 36 months. Materials and methods: the study included 191 people, 36.2 + 1.8 months of follow-up, and included the following stages: I stage (hospital) — from the moment of admission to the hospital for myocardial infarction; II stage (outpatient) — repeated visits 12 and 36 months after discharge from the hospital. The patients were divided into three groups: Group 1 — 69 patients with STEMI + hypertension; Group 2 — 67 patients with STEMI + hypertension + type 2 diabetes; Group 3 (comparison group) — 55 patients with hypertension and DM. Assessment of the plasma level of sST2 was carried out using kits of the company «Critical Diagnostics Presage RST2 Assay kit» (USA). The results were expressed in ng/ml. Results: the study showed that the level of the sST2 biomarker in patients with acute ST-segment elevation myocardial infarction(STEMI) and type 2 diabetes mellitus(DM2) had no significant differences between the groups. The sST2 values in these patients were significantly higher than in the comparison group. At the stage of hospitalization, the median sST2 in the first group (STEMI and HYPERTENSION) was 62.7 ng/ml, and in the second group (STEMI, hypertension and DM 2) — 56.3 ng / ml. After one year, the median decreased to 55.3 ng/ml and 52.4 ng/ml, respectively, and in the third year — to 46.4 ng/ml and 42.1 ng/ml. Correlations between sST2 values were not found in the acute period and after 12 and 36 months of pregnancy. A moderate association appeared in the 1st and 3rd year of follow-up. Conclusion: the study revealed that the level of the sST-2 marker in the groups of patients with STEMI\ + AH and STeMI + AH + DM at all stages of the study is comparable and significantly higher than in patients with hypertension + DM. During the study, a correlation was found between the levels of sST-2 outside the acute period of MI. However, there was no significant association between the marker levels at the hospital stage and its values at the end of the study. It was also found that the level of sST\-2 does not depend on the presence of diabetes and is associated with the final systolic, diastolic size and volume of.

South Russian Journal of Therapeutic PracticeVol. 6(1)
Rostov State Medical University (RU), City Hospital (GB)
Openalex Percentile: Top 93%
Apelin-related biomedical research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.